celecoxib has been researched along with Depression in 25 studies
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty outpatients with depression due to brucellosis with a Hamilton Depression Rating Scale score (HDRS) <19 participated in a randomized, double-blind, placebo-controlled trial and underwent 8 weeks of treatment with either celecoxib (200 mg bid) or placebo as an adjunctive to antibiotic therapy." | 9.20 | Celecoxib for the treatment of mild-to-moderate depression due to acute brucellosis: a double-blind, placebo-controlled, randomized trial. ( Akhondzadeh, S; Ashrafizadeh, SG; Entezari, P; Jafari, S; Rasoulinejad, M; Seddighi, S; Zeinoddini, A, 2015) |
| "Here, we aimed to compare the efficacy and safety of celecoxib, a selective inhibitor of COX-2, with diclofenac, a nonselective inhibitor of both COX-1 and COX-2 in reducing depressive symptoms and pain in breast cancer patients." | 9.20 | Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial. ( Akhondzadeh, S; Arya, P; Emami, SA; Esfandbod, M; Kashani, L; Kaviani, A; Mohammadinejad, P; Najafi, M; Zeinoddini, A, 2015) |
| "Celecoxib as add-on strategy resulted in a significant reduction of Hamilton Depression Scale scores compared to placebo." | 9.15 | Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression--no influence of celecoxib treatment. ( Arolt, V; Cerovecki, A; Dehning, S; Müller, N; Musil, R; Riedel, M; Schwarz, MJ; Spellmann, I, 2011) |
| "We evaluated the effect of the co-administration of fluoxetine (5 mg/kg) and flurbiprofen (5 mg/kg) or fluoxetine (5 mg/kg) and celecoxib (5 mg/kg) in the chronic escape deficit (CED) model of depression after 7 days of treatment." | 7.88 | Neither all anti-inflammatory drugs nor all doses are effective in accelerating the antidepressant-like effect of fluoxetine in an animal model of depression. ( Alboni, S; Benatti, C; Brunello, N; Capone, G; Tascedda, F, 2018) |
| "There was also no evidence that pre-treatment inflammation levels modified the effect of celecoxib augmentation versus placebo." | 7.01 | No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial. ( Baune, BT; Clark, SR; Fourrier, C; Hori, H; Louise, J; Mills, NT; Sampson, E; Schubert, KO, 2021) |
| "Depression was induced by IFNα (16 × 105 IU/kg, SC) for six consecutive days." | 5.51 | Celecoxib, ibuprofen, and indomethacin alleviate depression-like behavior induced by interferon-alfa in mice. ( Hajhashemi, V; Mesripour, A; Shahnooshi, S, 2019) |
| "Forty outpatients with depression due to brucellosis with a Hamilton Depression Rating Scale score (HDRS) <19 participated in a randomized, double-blind, placebo-controlled trial and underwent 8 weeks of treatment with either celecoxib (200 mg bid) or placebo as an adjunctive to antibiotic therapy." | 5.20 | Celecoxib for the treatment of mild-to-moderate depression due to acute brucellosis: a double-blind, placebo-controlled, randomized trial. ( Akhondzadeh, S; Ashrafizadeh, SG; Entezari, P; Jafari, S; Rasoulinejad, M; Seddighi, S; Zeinoddini, A, 2015) |
| "Here, we aimed to compare the efficacy and safety of celecoxib, a selective inhibitor of COX-2, with diclofenac, a nonselective inhibitor of both COX-1 and COX-2 in reducing depressive symptoms and pain in breast cancer patients." | 5.20 | Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial. ( Akhondzadeh, S; Arya, P; Emami, SA; Esfandbod, M; Kashani, L; Kaviani, A; Mohammadinejad, P; Najafi, M; Zeinoddini, A, 2015) |
| "Celecoxib as add-on strategy resulted in a significant reduction of Hamilton Depression Scale scores compared to placebo." | 5.15 | Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression--no influence of celecoxib treatment. ( Arolt, V; Cerovecki, A; Dehning, S; Müller, N; Musil, R; Riedel, M; Schwarz, MJ; Spellmann, I, 2011) |
| "We evaluated the effect of the co-administration of fluoxetine (5 mg/kg) and flurbiprofen (5 mg/kg) or fluoxetine (5 mg/kg) and celecoxib (5 mg/kg) in the chronic escape deficit (CED) model of depression after 7 days of treatment." | 3.88 | Neither all anti-inflammatory drugs nor all doses are effective in accelerating the antidepressant-like effect of fluoxetine in an animal model of depression. ( Alboni, S; Benatti, C; Brunello, N; Capone, G; Tascedda, F, 2018) |
| "There was also no evidence that pre-treatment inflammation levels modified the effect of celecoxib augmentation versus placebo." | 3.01 | No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial. ( Baune, BT; Clark, SR; Fourrier, C; Hori, H; Louise, J; Mills, NT; Sampson, E; Schubert, KO, 2021) |
| " Future clinical trials should investigate this association with maximum dosage of drugs, increased treatment duration, and monitoring of social and environmental changes." | 2.78 | NSAIDs are associated with lower depression scores in patients with osteoarthritis. ( Aneja, A; Farkouh, ME; Gandhi, S; Greenberg, J; Iyengar, RL; Mosovich, S; Razzouk, L; Thorpe, K, 2013) |
| "Treatment with celecoxib or naproxen did not improve depressive symptoms over time compared with placebo." | 2.77 | Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial. ( Drye, L; Fields, C; Lyketsos, C; Vaidya, V, 2012) |
| "Depression was induced by IFNα (16 × 105 IU/kg, SC) for six consecutive days." | 1.51 | Celecoxib, ibuprofen, and indomethacin alleviate depression-like behavior induced by interferon-alfa in mice. ( Hajhashemi, V; Mesripour, A; Shahnooshi, S, 2019) |
| "Depression is considered a neuropsychiatric condition which is associated with neuronal injury within specific brain regions." | 1.51 | COX-2 inhibition rescues depression-like behaviors via suppressing glial activation, oxidative stress and neuronal apoptosis in rats. ( Fan, C; Feng, YB; Li, Y; Shen, J; Song, Q; Wang, L; Wang, P; Yu, SY, 2019) |
| "AD and depression are crucially linked by neuroinflammation and cyclooxygenase II (COX-2) enzyme involvement is an intriguing field of research." | 1.48 | Sub-chronic celecoxib prevents soluble beta amyloid-induced depressive-like behaviour in rats. ( Bove, M; Mhillaj, E; Morgese, MG; Schiavone, S; Trabace, L; Tucci, P, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (16.00) | 29.6817 |
| 2010's | 15 (60.00) | 24.3611 |
| 2020's | 6 (24.00) | 2.80 |
| Authors | Studies |
|---|---|
| Strekalova, T | 1 |
| Pavlov, D | 1 |
| Trofimov, A | 1 |
| Anthony, DC | 1 |
| Svistunov, A | 1 |
| Proshin, A | 1 |
| Umriukhin, A | 1 |
| Lyundup, A | 1 |
| Lesch, KP | 1 |
| Cespuglio, R | 1 |
| Mesripour, A | 1 |
| Shahnooshi, S | 1 |
| Hajhashemi, V | 1 |
| Song, Q | 1 |
| Feng, YB | 1 |
| Wang, L | 1 |
| Shen, J | 1 |
| Li, Y | 1 |
| Fan, C | 1 |
| Wang, P | 1 |
| Yu, SY | 1 |
| Berk, M | 1 |
| Vieta, E | 1 |
| Dean, OM | 1 |
| Miller, AH | 2 |
| Pariante, CM | 1 |
| Husain, MI | 1 |
| Deakin, B | 1 |
| Chaudhry, IB | 1 |
| Mulsant, BH | 1 |
| Young, AH | 1 |
| Zhang, Y | 1 |
| Li, X | 1 |
| Zhou, K | 1 |
| Zhou, M | 1 |
| Xia, K | 1 |
| Xu, Y | 1 |
| Sun, X | 1 |
| Zhu, Y | 1 |
| Cui, C | 1 |
| Deng, C | 1 |
| Baune, BT | 1 |
| Sampson, E | 1 |
| Louise, J | 1 |
| Hori, H | 1 |
| Schubert, KO | 1 |
| Clark, SR | 1 |
| Mills, NT | 1 |
| Fourrier, C | 1 |
| Alamdarsaravi, M | 1 |
| Ghajar, A | 1 |
| Noorbala, AA | 1 |
| Arbabi, M | 1 |
| Emami, A | 1 |
| Shahei, F | 1 |
| Mirzania, M | 1 |
| Jafarinia, M | 1 |
| Afarideh, M | 1 |
| Akhondzadeh, S | 3 |
| Alboni, S | 1 |
| Benatti, C | 1 |
| Capone, G | 1 |
| Tascedda, F | 1 |
| Brunello, N | 1 |
| Morgese, MG | 1 |
| Schiavone, S | 1 |
| Bove, M | 1 |
| Mhillaj, E | 1 |
| Tucci, P | 1 |
| Trabace, L | 1 |
| Iyengar, RL | 1 |
| Gandhi, S | 1 |
| Aneja, A | 1 |
| Thorpe, K | 1 |
| Razzouk, L | 1 |
| Greenberg, J | 1 |
| Mosovich, S | 1 |
| Farkouh, ME | 1 |
| Maciel, IS | 1 |
| Silva, RB | 1 |
| Morrone, FB | 1 |
| Calixto, JB | 1 |
| Campos, MM | 1 |
| Santiago, RM | 1 |
| Barbiero, J | 1 |
| Martynhak, BJ | 1 |
| Boschen, SL | 1 |
| da Silva, LM | 1 |
| Werner, MF | 1 |
| Da Cunha, C | 1 |
| Andreatini, R | 1 |
| Lima, MM | 1 |
| Vital, MA | 1 |
| Kurhe, Y | 1 |
| Mahesh, R | 1 |
| Gupta, D | 1 |
| Jafari, S | 1 |
| Ashrafizadeh, SG | 1 |
| Zeinoddini, A | 2 |
| Rasoulinejad, M | 1 |
| Entezari, P | 1 |
| Seddighi, S | 1 |
| Mohammadinejad, P | 1 |
| Arya, P | 1 |
| Esfandbod, M | 1 |
| Kaviani, A | 1 |
| Najafi, M | 1 |
| Kashani, L | 1 |
| Emami, SA | 1 |
| Thomazeau, J | 1 |
| Rouquette, A | 1 |
| Martinez, V | 1 |
| Rabuel, C | 1 |
| Prince, N | 1 |
| Laplanche, JL | 1 |
| Nizard, R | 1 |
| Bergmann, JF | 1 |
| Perrot, S | 1 |
| Lloret-Linares, C | 1 |
| ELnahas, EM | 1 |
| Zeid, MS | 1 |
| Kawy, HS | 1 |
| Hendawy, N | 1 |
| Baher, W | 1 |
| Kellner, H | 1 |
| Musil, R | 1 |
| Schwarz, MJ | 1 |
| Riedel, M | 1 |
| Dehning, S | 1 |
| Cerovecki, A | 1 |
| Spellmann, I | 1 |
| Arolt, V | 1 |
| Müller, N | 1 |
| Fields, C | 1 |
| Drye, L | 1 |
| Vaidya, V | 1 |
| Lyketsos, C | 1 |
| Hu, F | 1 |
| Wang, X | 1 |
| Pace, TW | 1 |
| Wu, H | 1 |
| Iohom, G | 1 |
| Abdalla, H | 1 |
| O'Brien, J | 1 |
| Szarvas, S | 1 |
| Larney, V | 1 |
| Buckley, E | 1 |
| Butler, M | 1 |
| Shorten, GD | 1 |
| Myint, AM | 1 |
| Steinbusch, HW | 1 |
| Goeghegan, L | 1 |
| Luchtman, D | 1 |
| Kim, YK | 1 |
| Leonard, BE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Precision Psychiatry: Anti-inflammatory Medication in Immuno-metabolic Depression[NCT05415397] | Phase 3 | 140 participants (Anticipated) | Interventional | 2022-09-28 | Recruiting | ||
| Placebo-controlled, Dose-response Study of Ibuprofen Effects on Brain Function[NCT02507219] | Phase 2/Phase 3 | 24 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Salicylic Augmentation in Depression[NCT03152409] | Phase 2 | 74 participants (Anticipated) | Interventional | 2018-11-15 | Recruiting | ||
| Ambulatory Gynecologic Surgery: Finding the Optimal Postoperative Opioid Prescription[NCT03588910] | Phase 2 | 120 participants (Actual) | Interventional | 2018-08-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in amygdala activation following administration of placebo, 200mg of ibuprofen or 600mg of ibuprofen (NCT02507219)
Timeframe: 3-6 weeks
| Intervention | percent signal change (Mean) | |
|---|---|---|
| Left amygdala | Right amygdala | |
| Ibuprofen, 200mg | 0.21 | 0.23 |
| Ibuprofen, 600mg | 0.23 | 0.17 |
| Placebo | 0.20 | 0.23 |
By chart review, unscheduled interactions with the healthcare system related to pain will be counted.These will include phone calls related to pain, unscheduled visits to the office or emergency department (NCT03588910)
Timeframe: 1 week post operative
| Intervention | Unscheduled patient contacts (Number) |
|---|---|
| Number of Oxycodone Tablets Typically Prescribed | 1 |
| Half the Number of Oxycodone Tablets Typically Prescribed | 4 |
During the survey phone call on day 7, participants will be asked to report the total number of oxycodone tablets used since the surgery. (NCT03588910)
Timeframe: 7 days post-operative
| Intervention | Oxycodone Tablets (Median) |
|---|---|
| Number of Oxycodone Tablets Typically Prescribed | 2.5 |
| Half the Number of Oxycodone Tablets Typically Prescribed | 2.0 |
During the survey phone call on day 1, participants will be asked to report the total number of oxycodone tablets use since the surgery. (NCT03588910)
Timeframe: 24 hours post-operative
| Intervention | Oxycodone Tablets (Median) |
|---|---|
| Number of Oxycodone Tablets Typically Prescribed | 1.0 |
| Half the Number of Oxycodone Tablets Typically Prescribed | 1.0 |
Participants will be surveyed during the phone call survey to rate pain score on a scale from 0 (no pain), to 10 (severe pain) (NCT03588910)
Timeframe: 1 day post operative
| Intervention | Score on Numeric Pain Scale (Median) |
|---|---|
| Number of Oxycodone Tablets Typically Prescribed | 5.0 |
| Half the Number of Oxycodone Tablets Typically Prescribed | 5 |
Participants will be surveyed during the phone call survey to rate pain score on a scale from 0 (no pain), to 10 (severe pain) (NCT03588910)
Timeframe: 7 days post operative
| Intervention | Score on Numeric Pain Scale (Median) |
|---|---|
| Number of Oxycodone Tablets Typically Prescribed | 2.0 |
| Half the Number of Oxycodone Tablets Typically Prescribed | 1.3 |
8 trials available for celecoxib and Depression
| Article | Year |
|---|---|
No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial.
Topics: Antidepressive Agents; Australia; C-Reactive Protein; Celecoxib; Depression; Depressive Disorder, Ma | 2021 |
Efficacy and safety of celecoxib monotherapy for mild to moderate depression in patients with colorectal cancer: A randomized double-blind, placebo controlled trial.
Topics: Adult; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Depression; Double-Blind Method | 2017 |
NSAIDs are associated with lower depression scores in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Depression; Doub | 2013 |
NSAIDs are associated with lower depression scores in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Depression; Doub | 2013 |
NSAIDs are associated with lower depression scores in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Depression; Doub | 2013 |
NSAIDs are associated with lower depression scores in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Depression; Doub | 2013 |
Celecoxib for the treatment of mild-to-moderate depression due to acute brucellosis: a double-blind, placebo-controlled, randomized trial.
Topics: Adult; Anti-Bacterial Agents; Antidepressive Agents; Brucellosis; Celecoxib; Cyclooxygenase 2 Inhibi | 2015 |
Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial.
Topics: Analgesics; Antidepressive Agents; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; Cycloox | 2015 |
Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression--no influence of celecoxib treatment.
Topics: Adult; Aged; Antidepressive Agents; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Depres | 2011 |
Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibi | 2012 |
The associations between severity of early postoperative pain, chronic postsurgical pain and plasma concentration of stable nitric oxide products after breast surgery.
Topics: Acetaminophen; Adult; Aged; Analgesia; Anxiety; Breast Neoplasms; Bupivacaine; Celecoxib; Chronic Di | 2006 |
17 other studies available for celecoxib and Depression
| Article | Year |
|---|---|
Hippocampal Over-Expression of Cyclooxygenase-2 (COX-2) Is Associated with Susceptibility to Stress-Induced Anhedonia in Mice.
Topics: Anhedonia; Animals; Antidepressive Agents; Celecoxib; Citalopram; Cyclooxygenase 2; Depression; Hind | 2022 |
Celecoxib, ibuprofen, and indomethacin alleviate depression-like behavior induced by interferon-alfa in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Celecoxib; Depression; Disease M | 2019 |
COX-2 inhibition rescues depression-like behaviors via suppressing glial activation, oxidative stress and neuronal apoptosis in rats.
Topics: Animals; Antidepressive Agents; Apoptosis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2019 |
Anti-inflammatory treatment of bipolar depression: promise and disappointment.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antirheumatic Agents; Biomarkers; Bipolar Disorder; | 2020 |
Trial failures of anti-inflammatory drugs in depression.
Topics: Anti-Inflammatory Agents; Bipolar Disorder; Celecoxib; Depression; Humans; Minocycline | 2020 |
Trial failures of anti-inflammatory drugs in depression - Authors' reply.
Topics: Anti-Inflammatory Agents; Bipolar Disorder; Celecoxib; Depression; Humans; Minocycline | 2020 |
Influence of Experimental Autoimmune Prostatitis on Sexual Function and the Anti-inflammatory Efficacy of Celecoxib in a Rat Model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Diseases; Celecoxib; Depression; Diseas | 2020 |
Neither all anti-inflammatory drugs nor all doses are effective in accelerating the antidepressant-like effect of fluoxetine in an animal model of depression.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Behavior, Animal; Celecoxib; Depression; D | 2018 |
Sub-chronic celecoxib prevents soluble beta amyloid-induced depressive-like behaviour in rats.
Topics: Amyloid beta-Peptides; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Depression; Male; Rats; Sero | 2018 |
Synergistic effects of celecoxib and bupropion in a model of chronic inflammation-related depression in mice.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Antidepressive Agents; Behavior, Animal; Brain-Derive | 2013 |
Antidepressant-like effect of celecoxib piroxicam in rat models of depression.
Topics: Animals; Antidepressive Agents; Celecoxib; Depression; Disease Models, Animal; Exploratory Behavior; | 2014 |
Effect of a selective cyclooxygenase type 2 inhibitor celecoxib on depression associated with obesity in mice: an approach using behavioral tests.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Celecoxib; Cyclooxygenase 2 Inhibitors; Depression | 2014 |
Acute pain Factors predictive of post-operative pain and opioid requirement in multimodal analgesia following knee replacement.
Topics: Acute Pain; Aged; Amides; Analgesics; Analgesics, Opioid; Anesthetics, Local; Anxiety; Arthroplasty, | 2016 |
Celecoxib attenuates depressive-like behavior associated with immunological liver injury in C57BL/6 mice through TNF-α and NF-κb dependent mechanisms.
Topics: Animals; Autoimmune Diseases; Behavior, Animal; Brain; Caspase 3; Celecoxib; Depression; Dose-Respon | 2016 |
[Rheumatoid arthritis and depression].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antidepressive Agents, Second- | 2009 |
Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Depression; Dose-Response Relationship, Drug; Drug In | 2005 |
Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression.
Topics: Animals; Behavior, Animal; Brain Chemistry; Celecoxib; Cyclooxygenase Inhibitors; Cytokines; Depress | 2007 |